12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Bendavia: Phase II started

Stealth Peptides began the double-blind, placebo-controlled, international Phase II EMBRACE-STEMI trial to evaluate 0.05 mg/kg/hour IV Bendavia in about 300 patients who...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >